OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zhang on Key Phase 3 Trials for PARP Inhibitors in mCRPC

March 8th 2023

Tian Zhang, MD, MHS, discusses key phase 3 trials evaluating PARP inhibitors in the treatment of metastatic castration-resistance prostate cancer.

Dr. Pavlick on the IGNYTE Trial in Patients With Melanoma Following Anti–PD-1 Progression

March 8th 2023

Anna C. Pavlick, DO, discusses the phase 2 IGNYTE trial examining vusolimogene oderparepvec in combination with nivolumab in 3 tumor-specific cohorts, including 1 featuring patients with anti–PD-1–failed cutaneous melanoma.

Dr. Mascarenhas on the Role of Pacritinib in Myelofibrosis

March 8th 2023

John Mascarenhas, MD, discusses the role of pacritinib in patients with myelofibrosis.

Dr. Hussain on Retrospective Analysis of the ARASENS trial in mHSPC

March 8th 2023

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Dr. Godara on Treatment Strategies Following First Relapse in Multiple Myeloma

March 8th 2023

Amandeep Godara, MBBS, discusses the current treatment strategies following first relapse for patients with multiple myeloma.

Dr. Brahmer on Treatment Following Progression on First-line Immunotherapy in NSCLC

March 8th 2023

Julie Renee Brahmer, MD, discusses clinical trials investigating treatment options for patients with non–small cell lung cancer following progression after first-line immunotherapy.

Dr. Galsky on the Rationale for the CheckMate-274 Trial in Urothelial Cancer

March 8th 2023

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate-274 trial in patients with urothelial cancer.

Dr. Tombal on Darolutamide Monotherapy in Newly Diagnosed mHSPC

March 8th 2023

Bertrand Tombal, MD, PhD, discusses the rationale for conducting a phase 2 study of darolutamide monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer.

Dr. Torka on the Role of Pirtobrutinib in R/R MCL

March 8th 2023

Pallawi Torka, MD, discusses the clinical implications of the FDA approval of pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma.

Dr. Owen on Choosing Between BTK Inhibitors in CLL

March 8th 2023

Carolyn Owen, MD, FRCPC, discusses factors to consider when deciding whether to use the BTK inhibitors ibrutinib, acalabrutinib, or zanubrutinib in patients with chronic lymphocytic leukemia.

Dr. Ahn on the Evolution of First-line Treatment Options in HCC

March 7th 2023

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Dr. Awan Discusses Distinguishes Among Available BTK Inhibitors in MCL

March 7th 2023

Farrukh Awan, MD, discusses the potential use of BTK inhibitors in the management of mantle cell leukemia.

Dr. Giralt on the Rationale of the Karmma-3 trial of Ide-cel in R/R Myeloma

March 6th 2023

Sergio A. Giralt, MD, discusses the rationale for investigating idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Dr. Shah on the Safety of LV20.19 CAR T-cell Therapy in R/R MCL

March 6th 2023

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

Dr. Jain on Unmet Needs in Patients with Myelofibrosis Undergoing Allo-SCT

March 6th 2023

Tania Jain, MBBS, discusses the unmet needs for patients with myelofibrosis who receive an allogeneic stem cell transplant.

Dr. Ahn on the Selection of First-line ICI-Based Combinations in HCC

March 6th 2023

Daniel H. Ahn, DO, discusses the importance of drug toxicity when selecting between first-line immune checkpoint inhibitor–based regimens in hepatocellular carcinoma.

Dr. Park on the Increasing Use of Biomarker Testing and Radiotheranostics in Prostate Cancer

March 6th 2023

Chandler Park, MD, MSc, FACP, discusses how the emerging field of radiotheranostics and increasing utilization of biomarker testing will improve the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Foote on the Quest to Determine Optimal Sequencing in Late-line mCRC

March 6th 2023

Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.

Dr. Carey on the Response-Guided Therapy in HER2+ Breast Cancer

March 5th 2023

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

Dr. Borgen on the Importance of Addressing Opioid Use in Breast Cancer Care

March 5th 2023

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.